AtaiBeckley Inc. Common Stock
ATAI
$7.28
-1.49%
AtaiBeckley Inc. is a clinical-stage biopharmaceutical company focused on developing rapid-acting and convenient treatments for mental health conditions, with a pipeline including BPL-003 for treatment-resistant depression, VLS-01 for TRD, and EMP-01 for social anxiety disorder. As a pioneer in psychedelic-inspired therapeutics, it holds a distinct position in the biotechnology industry, targeting a large unmet need in mental health. The current investor narrative centers on the transformative acquisition by Eli Lilly, announced in July 2026, which validates its lead asset and provides a clear exit path for shareholders, driving significant stock appreciation and strategic interest in the company's novel approach.…
ATAI
AtaiBeckley Inc. Common Stock
$7.28
Related headlines
Investment Opinion: Should I buy ATAI Today?
Based on the analysis, the recommendation is a Hold. The Eli Lilly acquisition provides a floor and validates the pipeline, but the extreme valuation and lack of revenue limit upside potential. The average analyst target of $8.10 implies a modest 9.6% upside, and the consensus is 'hold', reflecting cautious optimism. The stock is suitable for investors with a high risk tolerance who believe in the long-term potential of psychedelic-inspired mental health treatments.
Sign up to view all
ATAI 12-Month Price Forecast
The AI assessment is neutral with medium confidence. The acquisition by Eli Lilly is a strong positive catalyst that reduces downside risk, but the extreme valuation and lack of revenue make the stock vulnerable to negative news. The stock is likely to trade in a range near the analyst target, with upside limited to the high target of $9.25 and downside protected by the acquisition floor. To upgrade to a bullish stance, we would need to see successful acquisition completion and positive clinical data, while a downgrade would occur if the acquisition fails or trials disappoint.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on AtaiBeckley Inc. Common Stock's 12-month outlook, with a consensus price target around $8.10 and implied upside of +11.3% versus the current price.
Average Target
$8.10
0 analysts
Implied Upside
+11.3%
vs. current price
Analyst Count
—
covering this stock
Price Range
$7 - $9
Analyst target range
With 7 analysts covering the stock, the consensus recommendation is 'hold' (mean score of 2.86 out of 5), reflecting cautious optimism post-acquisition. The average target price is $8.10, implying a +9.6% upside from the current price of $7.39, while the low target of $7.45 is near the current price and the high target of $9.25 suggests a +25.2% upside. The relatively narrow range between low and high targets (7.45 to 9.25) indicates moderate uncertainty, but the recent acquisition by Eli Lilly at a premium likely caps downside, with the high target assuming successful integration and pipeline progress.
Bulls vs Bears: ATAI Investment Factors
AtaiBeckley presents a compelling bull case driven by the Eli Lilly acquisition, which validates its pipeline and provides a clear exit path, alongside strong price momentum and a healthy balance sheet. However, the bear case highlights an extreme valuation with no revenue, significant losses, and high volatility, which could lead to sharp corrections if pipeline or acquisition risks materialize. Currently, the bull case has stronger evidence in the near term due to the acquisition floor, but the long-term thesis hinges on the successful development and commercialization of its mental health therapies. The most important tension is whether the acquisition premium and pipeline potential justify the astronomical PS ratio, which will be resolved by clinical data and integration progress.
Bullish
- Eli Lilly acquisition validates pipeline: The transformative acquisition by Eli Lilly, announced in July 2026, provides a clear exit path and validates the potential of AtaiBeckley's lead asset, BPL-003. This strategic move by a major pharma player underscores the value of the company's novel approach to mental health, driving a significant stock appreciation.
- Strong price momentum and relative strength: The stock has surged 62.06% over the past year, vastly outperforming the S&P 500's 18.65% gain. With a 3-month change of 87.09% and a 6-month change of 117.99%, the stock is in a robust uptrend, reflecting strong investor confidence and positive sentiment.
- Near 52-week high with limited downside: Trading at $7.39, just 0.8% below its 52-week high of $7.45, the stock shows strong momentum. The low analyst target of $7.45 aligns with the current price, suggesting that the acquisition premium provides a floor, limiting downside risk.
- High gross margin indicates scalability: Despite being pre-revenue, the company boasts a gross margin of 75.25%, implying that once products reach the market, the cost structure could be highly favorable. This suggests potential for strong profitability if pipeline candidates succeed.
Bearish
- Extreme valuation with no revenue: With a PS ratio of 226.59 and EV/Sales of 559.19, the market is pricing in enormous future revenue that is far from guaranteed. The company has minimal current revenue, making the valuation highly speculative and vulnerable to any pipeline setbacks.
- Significant operating losses: The company reported a net margin of -161.42% and an operating margin of -24.40%, reflecting heavy investment in R&D. With a trailing EPS of -$0.71, losses are expected to continue as clinical trials advance, potentially requiring further dilution.
- High volatility and beta: With a beta of 1.552, the stock is 55% more volatile than the market, amplifying both upside and downside. The max drawdown of -48.06% highlights the potential for significant losses during market downturns or negative news.
- Cautious analyst sentiment: The consensus recommendation is 'hold' with a mean score of 2.86 out of 5, indicating that analysts are not overly enthusiastic post-acquisition. The average target price of $8.10 implies only a modest 9.6% upside, suggesting limited near-term appreciation.
ATAI Technical Analysis
The stock has exhibited a robust long-term uptrend, with a 1-year price change of +62.06%, significantly outperforming the S&P 500's +18.65% over the same period. Currently trading at $7.39, the stock is near its 52-week high of $7.45, representing 99.2% of the 52-week range, indicating strong momentum and bullish sentiment, though it may also suggest overextension in the near term. The stock's beta of 1.552 implies it is 55% more volatile than the market, amplifying both upside and downside risks.
Beta
1.55
1.55x market volatility
Max Drawdown
-48.1%
Largest decline past year
52-Week Range
$3-$7
Price range past year
Annual Return
+61.1%
Cumulative gain past year
| Period | ATAI Return | S&P 500 |
|---|---|---|
| 1m | +0.4% | -0.9% |
| 3m | +92.6% | +5.6% |
| 6m | +90.6% | +15.0% |
| 1y | +61.1% | +18.1% |
| ytd | +88.1% | +12.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ATAI Fundamental Analysis
As a clinical-stage biopharmaceutical company, AtaiBeckley has no approved products, resulting in minimal revenue; the most recent quarterly revenue is not available, but the PS ratio of 226.59 and EV/Sales of 559.19 reflect the market's valuation of future potential rather than current sales. The company remains unprofitable, with a trailing EPS of -$0.71 and a net margin of -161.42%, indicating significant investment in R&D and clinical trials. However, the gross margin of 75.25% suggests that once products reach market, the cost structure could be favorable, though operating losses are expected to continue as trials advance.
Quarterly Revenue
N/A
N/A
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
N/A
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ATAI Overvalued?
Given the negative net income, the price-to-sales (PS) ratio is the most appropriate valuation metric, currently at 226.59, which is extremely high and reflects the market's pricing of substantial future revenue growth from its pipeline. The forward PE of -15.08 is not meaningful due to expected losses, but the PEG ratio of -0.0066 indicates that earnings growth is not yet on the horizon. Compared to the industry average PS ratio (not provided), the stock trades at a significant premium, justified by the potential of its novel therapies and the acquisition premium from Eli Lilly.
PE
-1.4x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-1.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are substantial given the company's clinical-stage status. With no approved products, revenue is minimal, leading to a PS ratio of 226.59 and EV/Sales of 559.19, which are extremely high and reflect expectations of future success. The company is unprofitable, with a trailing EPS of -$0.71 and a net margin of -161.42%, indicating heavy cash burn on R&D. However, the low debt-to-equity ratio of 0.0093 and current ratio of 11.74 provide a strong liquidity buffer, reducing near-term solvency risk. The main financial risk is dilution from future capital raises to fund trials, which could pressure the stock price.